59744-08-0

Basic information

• Product Name: 1,3-Butanediol, 1-(4-methylbenzenesulfonate)
• CAS NO: 59744-08-0
• Molecular Formula: C11H16O4S
• Molecular Weight: 244.312
• Mol File: 59744-08-0.mol
• Article Data: 20

Chemical Properties

• CAS DataBase Reference: 1,3-Butanediol, 1-(4-methylbenzenesulfonate)(CAS DataBase Reference)
• NIST Chemistry Reference: 1,3-Butanediol, 1-(4-methylbenzenesulfonate)(59744-08-0)
• EPA Substance Registry System: 1,3-Butanediol, 1-(4-methylbenzenesulfonate)(59744-08-0)

Safety Data

• Hazardous Substances Data: 59744-08-0(Hazardous Substances Data)

Upstream product

• 18826-95-4 1.3-butanediol 
• 98-59-9 p-toluenesulfonyl chloride 
• 71-36-3 butan-1-ol 
• 82964-98-5 2-(p-chlorbenzolsulfonyloxy)-4-(p-toluolsulfonyloxy)butan 

Downstream Products

• 251637-43-1 3-[(tetrahydro-2H-pyran-2-yl)oxy]-1-butanol 4-methylbenzenesulfonate 
• 1034267-00-9 4-(4-phenylpiperazin-1-yl)butan-2-ol 
• 1034266-96-0 4-(4-(2-methoxyphenyl)piperazin-1-yl)butan-2-ol 
• 1034266-98-2 4-(4-(4-fluorophenyl)piperazin-1-yl)butan-2-ol 
• 1034266-94-8 4-(4-(3-(trifluoromethyl)phenyl)piperazin-1-yl)butan-2-ol 
• 166273-40-1 6-Hydroxy-heptane acid phenylester 
• 865864-31-9 4-(benzyl(methyl)amino)butan-2-ol 
• 93293-37-9 4-[(phenylmethyl)amino]-2-butanol 
• 1312789-89-1 (3R)-3-acetoxybutyl 4-methylbenzenesulfonate 
• 82614-88-8 (S)-3-hydroxybutyl toluene-4-sulphonate 

Relevant articles and documents

Small-molecule anti-HIV-1 agents based on HIV-1 capsid proteins

The capsid of human immunodeficiency virus type 1 (HIV-1) is a shell that encloses viral RNA and is highly conserved among many strains of the virus. It forms a conical structure by assembling oligomers of capsid (CA) proteins. CA dysfunction is expected to be an important target of suppression of HIV-1 replication, and it is important to understand a new mechanism that could lead to the CA dysfunction. A drug targeting CA however, has not been developed to date. Hydrophobic interactions between two CA molecules via Trp184/Met185 in CA were recently reported to be important for stabilization of the multimeric structure of CA. In the present study, a small molecule designed by in silico screening as a dipeptide mimic of Trp184 and Met185 in the interaction site, was synthesized and its significant anti-HIV-1 activity was confirmed. Structure activity relationship (SAR) studies of its derivatives were performed and provided results that are expected to be useful in the future design and development of novel anti-HIV agents targeting CA.

Regioselective Sulfonylation/Acylation of Carbohydrates Catalyzed by FeCl3 Combined with Benzoyltrifluoroacetone and Its Mechanism Study

A catalytic amount of FeCl3 combined with benzoyl trifluoroacetone (Hbtfa) (FeCl3/Hbtfa = 1/2) was used to catalyze sulfonylation/acylation of diols and polyols using diisopropylethylamine (DIPEA) or potassium carbonate (K2CO3) as a base. The catalytic system exhibited high catalytic activity, leading to excellent isolated yields of sulfonylation/acylation products with high regioselectivities. Mechanism studies indicated that FeCl3 initially formed [Fe(btfa)3] (btfa = benzoyl trifluoroacetonate) with twice the amount of Hbtfa under basic conditions in the solvent acetonitrile at room temperature. Then, Fe(btfa)3 and two hydroxyl groups of the substrates formed a five- or six-membered ring intermediate in the presence of the base. The subsequent reaction between the cyclic intermediate and a sulfonylation reagent led to the selective sulfonylation of the substrate. All key intermediates were captured in the high-resolution mass spectrometry assay, therefore demonstrating this mechanism for the first time.

2-AMINO-QUINOLINE DERIVATIVES

Described herein are 2-amino-quinoline derivatives that are agonists of toll-like receptors 7 and 8 (TLR7/8), pharmaceutical compositions, and methods of use of the compounds and compositions to treat various diseases, such as viral, cancer, and allergic diseases, in need thereof by administering a therapeutically effective amount of a 2-amino-quinoline derivative.